FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282983722> ?p ?o ?g. }

• W4282983722 endingPage "602" @default.
• W4282983722 startingPage "602" @default.
• W4282983722 abstract "Abstract In the 23andMe genetic database, associations were observed for CD200R1 variants and autoimmune and cancer traits with opposing directionality. These data suggest that CD200R1 may be a pivotal checkpoint in immunosurveillance of cancer and a promising therapeutic target. CD200R1 is expressed widely on human T cells and myeloid cells; and binds to its cognate ligand CD200 to suppress the activity of immune cells. Elevated expression of CD200R1 was observed on tumor-infiltrating lymphocytes relative to peripheral blood mononuclear cells (PBMCs) from cancer patients. While the expression of CD200R1 and its ligand CD200 are well characterized, the downstream immunosuppressive role for CD200R1 in human tumors or the potentiation of anti-tumor T cell function by targeting of CD200R1 is not well understood. To test the therapeutic potential of inhibiting the CD200R1 pathway we developed 23ME-00610, a fully humanized monoclonal antibody that binds to all functionally relevant isoforms and haplotypes of CD200R1 with high affinity (KD values &lt; 0.1 nM), to target tumors that are reliant on the CD200R1 immunosuppressive pathway. 23ME-00610 completely displaced the ligand CD200 from CD200R1 in cell-based flow cytometry assays with blocking IC50 values that ranged from 0.32 to 1.04 nM depending on the concentration of CD200 ligand present, and inhibited downstream signaling through the adaptor protein DOK2 in a reporter-based assay. Functionally, 23ME-00610 reversed CD200-mediated suppression of chronically stimulated primary T cells. In addition, 23ME-00610 enhanced PBMC-mediated tumor killing with a mean EC50 of 2.09 nM using methods of real-time measurement of cytotoxicity of human CD200-expressing tumor cells when compared to control antibodies. Moreover, 23ME-00610 promoted IFNγ production, a key functional anti-tumor T cell cytokine, in cancer patients’-derived PBMCs. Taken together, these results demonstrate that 23ME-00610 has the potential to reverse CD200-mediated immunosuppression in the TME to enhance anti-tumor T-cell functions in cancer patients. Citation Format: Jill Fenaux, Yao-ming Huang, Cristina Melero, Wei-Jen Chung, Suk Lee, Dina Ayupova, Mauro Poggio, Dylan Glatt, Zuoan Yi, Cecilia Lay, Maike Schmidt, Sophia R. Majeed, Germaine Fuh, Alice Chen, Sushil Kumar. 23ME-00610 is a first-in-class monoclonal antibody that targets the CD200R1 immune checkpoint to enhance T cell-mediated antitumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 602." @default.
• W4282983722 created "2022-06-17" @default.
• W4282983722 creator A5000144044 @default.
• W4282983722 creator A5021983025 @default.
• W4282983722 creator A5023783774 @default.
• W4282983722 creator A5027003060 @default.
• W4282983722 creator A5030990056 @default.
• W4282983722 creator A5032223418 @default.
• W4282983722 creator A5032358498 @default.
• W4282983722 creator A5033173180 @default.
• W4282983722 creator A5037704758 @default.
• W4282983722 creator A5045409088 @default.
• W4282983722 creator A5058362236 @default.
• W4282983722 creator A5059946745 @default.
• W4282983722 creator A5063004323 @default.
• W4282983722 creator A5080950921 @default.
• W4282983722 creator A5088296076 @default.
• W4282983722 date "2022-06-15" @default.
• W4282983722 modified "2023-10-18" @default.
• W4282983722 title "Abstract 602: 23ME-00610 is a first-in-class monoclonal antibody that targets the CD200R1 immune checkpoint to enhance T cell-mediated antitumor activity" @default.
• W4282983722 doi "https://doi.org/10.1158/1538-7445.am2022-602" @default.
• W4282983722 hasPublicationYear "2022" @default.
• W4282983722 type Work @default.
• W4282983722 citedByCount "0" @default.
• W4282983722 crossrefType "journal-article" @default.
• W4282983722 hasAuthorship W4282983722A5000144044 @default.
• W4282983722 hasAuthorship W4282983722A5021983025 @default.
• W4282983722 hasAuthorship W4282983722A5023783774 @default.
• W4282983722 hasAuthorship W4282983722A5027003060 @default.
• W4282983722 hasAuthorship W4282983722A5030990056 @default.
• W4282983722 hasAuthorship W4282983722A5032223418 @default.
• W4282983722 hasAuthorship W4282983722A5032358498 @default.
• W4282983722 hasAuthorship W4282983722A5033173180 @default.
• W4282983722 hasAuthorship W4282983722A5037704758 @default.
• W4282983722 hasAuthorship W4282983722A5045409088 @default.
• W4282983722 hasAuthorship W4282983722A5058362236 @default.
• W4282983722 hasAuthorship W4282983722A5059946745 @default.
• W4282983722 hasAuthorship W4282983722A5063004323 @default.
• W4282983722 hasAuthorship W4282983722A5080950921 @default.
• W4282983722 hasAuthorship W4282983722A5088296076 @default.
• W4282983722 hasConcept C116569031 @default.
• W4282983722 hasConcept C121608353 @default.
• W4282983722 hasConcept C137061746 @default.
• W4282983722 hasConcept C159654299 @default.
• W4282983722 hasConcept C170493617 @default.
• W4282983722 hasConcept C185592680 @default.
• W4282983722 hasConcept C202751555 @default.
• W4282983722 hasConcept C203014093 @default.
• W4282983722 hasConcept C2777701055 @default.
• W4282983722 hasConcept C2780674031 @default.
• W4282983722 hasConcept C2780851360 @default.
• W4282983722 hasConcept C502942594 @default.
• W4282983722 hasConcept C542903549 @default.
• W4282983722 hasConcept C54355233 @default.
• W4282983722 hasConcept C55493867 @default.
• W4282983722 hasConcept C86803240 @default.
• W4282983722 hasConcept C8891405 @default.
• W4282983722 hasConcept C95444343 @default.
• W4282983722 hasConcept C96232424 @default.
• W4282983722 hasConceptScore W4282983722C116569031 @default.
• W4282983722 hasConceptScore W4282983722C121608353 @default.
• W4282983722 hasConceptScore W4282983722C137061746 @default.
• W4282983722 hasConceptScore W4282983722C159654299 @default.
• W4282983722 hasConceptScore W4282983722C170493617 @default.
• W4282983722 hasConceptScore W4282983722C185592680 @default.
• W4282983722 hasConceptScore W4282983722C202751555 @default.
• W4282983722 hasConceptScore W4282983722C203014093 @default.
• W4282983722 hasConceptScore W4282983722C2777701055 @default.
• W4282983722 hasConceptScore W4282983722C2780674031 @default.
• W4282983722 hasConceptScore W4282983722C2780851360 @default.
• W4282983722 hasConceptScore W4282983722C502942594 @default.
• W4282983722 hasConceptScore W4282983722C542903549 @default.
• W4282983722 hasConceptScore W4282983722C54355233 @default.
• W4282983722 hasConceptScore W4282983722C55493867 @default.
• W4282983722 hasConceptScore W4282983722C86803240 @default.
• W4282983722 hasConceptScore W4282983722C8891405 @default.
• W4282983722 hasConceptScore W4282983722C95444343 @default.
• W4282983722 hasConceptScore W4282983722C96232424 @default.
• W4282983722 hasIssue "12_Supplement" @default.
• W4282983722 hasLocation W42829837221 @default.
• W4282983722 hasOpenAccess W4282983722 @default.
• W4282983722 hasPrimaryLocation W42829837221 @default.
• W4282983722 hasRelatedWork W2979186475 @default.
• W4282983722 hasRelatedWork W2984962695 @default.
• W4282983722 hasRelatedWork W2994575502 @default.
• W4282983722 hasRelatedWork W3040651070 @default.
• W4282983722 hasRelatedWork W3161615519 @default.
• W4282983722 hasRelatedWork W4200208575 @default.
• W4282983722 hasRelatedWork W4225811843 @default.
• W4282983722 hasRelatedWork W4289890608 @default.
• W4282983722 hasRelatedWork W4327702748 @default.
• W4282983722 hasRelatedWork W4380224720 @default.
• W4282983722 hasVolume "82" @default.
• W4282983722 isParatext "false" @default.
• W4282983722 isRetracted "false" @default.
• W4282983722 workType "article" @default.